Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
IRVINE, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2026 and updated its full year guidance for the year ending December 31, 2026.
Covered in this story
Call it yourself
No calls on $BBNX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Beta Bionics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.